Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 91 of the 92 references it cites were found in a registry or an index.

Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases

Open access
Perez, Barbara A., Shutterly, Alison, Chan, Ying Kai, Byrne, Barry J., Corti, Manuela · 2020 · Brain Sciences

Abstract

Recently, adeno-associated virus (AAV)-mediated gene therapies have attracted clinical interest for treating neurodegenerative diseases including spinal muscular atrophy (SMA), Canavan disease (CD), Parkinson’s disease (PD), and Friedreich’s ataxia (FA). The influx of clinical findings led to the first approved gene therapy for neurodegenerative disorders in 2019 and highlighted new safety concerns for patients. Large doses of systemically administered AAV stimulate host immune responses, resulting in anti-capsid and anti-transgene immunity with implications for transgene expression, treatment longevity, and patient safety. Delivering lower doses directly to the central nervous system (CNS) is a promising alternative, resulting in higher transgene expression with decreased immune responses. However, neuroinflammatory responses after CNS-targeted delivery of AAV are a critical concern. Reported signs of AAV-associated neuroinflammation in preclinical studies include dorsal root ganglion (DRG) and spinal cord pathology with mononuclear cell infiltration. In this review, we discuss ways to manage neuroinflammation, including choice of AAV capsid serotypes, CNS-targeting routes of delivery, genetic modifications to the vector and/or transgene, and adding immunosuppressive strategies to clinical protocols. As additional gene therapies for neurodegenerative diseases enter clinics, tracking biomarkers of neuroinflammation will be important for understanding the impact immune reactions can have on treatment safety and efficacy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/brainsci10020119

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Comparison of central nervous system (CNS)-directed dosing strategies. (a) Schematic diagram of relative location of cerebrospinal fluid (CSF)-targeting injections. (b) Table of pros and cons between common routes of CSF delivery.
Figure 1 Comparison of central nervous system (CNS)-directed dosing strategies. (a) Schematic diagram of relative location of cerebrospinal fluid (CSF)-targeting injections. (b) Table of pros and cons between common routes of CSF delivery.CC BY · PubMed Central
Figure 2 Schematic overview of possible strategies to mitigate immune responses at various stages during gene therapy. (a) Pre-dosing considerations include vector design and treatment strategies to prepare the immune system for adeno-associated virus (AAV) exposure. (b) During dosing of the vector, the route of administration is selected in consideration of disease-relevant target tissues as to minimize toxicities from transgene overexpression or transgene expression in non-target tissues. (c) Post-dosing considerations include selection of immune management strategies that protect trangene expression and neural tissue and decrease neuroinflammation. .
Figure 2 Schematic overview of possible strategies to mitigate immune responses at various stages during gene therapy. (a) Pre-dosing considerations include vector design and treatment strategies to prepare the immune system for adeno-associated virus (AAV) exposure. (b) During dosing of the vector, the route of administration is selected in consideration of disease-relevant target tissues as to minimize toxicities from transgene overexpression or transgene expression in non-target tissues. (c) Post-dosing considerations include selection of immune management strategies that protect trangene expression and neural tissue and decrease neuroinflammation. .CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 92 references

Research works printed but not linked: 9

  1. Corti, M., Norman, S., Coleman, K., Liberati, C., Elder, M., Escolar, M., Clement, N., Clever, B., Byrne, B., and Gao, G. (2018). Immune Blockade in CNS Gene Therapy Improves Safety and Clinical Outcome, Cell Press. Molecular Therapy.
  2. Nair, J., Freeman, D., Davis, I., McParland, T., Pope, M., Perez, B., Rodriguez-Lebron, E., Coleman, K., Subramony, S., and Byrne, B. (2019). AAV9 Biodistribution with Different Routes of CNS Administration in Rodents, Cell Press. Molecular Therapy.
  3. Perez, B.A., Coleman, K.E., Wichman, M.B., Futch, K.N., Mandolini, K.E., Cravey, L.D., Nair, J., Cloutier, D.A., Lynch, D., and Byrne, B.J. (2019). Management of Preexisting Immunity to AAV9 in Friedreich’s Ataxia, Cell Press. Molecular Therapy.
  4. Letizia, A., Chan, Y.K., Graveline, A., and Church, G. (2019). Engineering AAV Vectors to Reduce CD8+ T Cell Responses Following Intramuscular Injection in Mice, Cell Press. Molecular Therapy.
  5. Chan, Y.K., Wang, S., Letizia, A., Chan, Y., Lim, E., Graveline, A., Verdera, H.C., Alphonse, P., Xue, Y., and Chiang, J. (2019). Reducing AAV-Mediated Immune Responses and Pathology in a Subretinal Pig Model by Engineering the Vector Genome, Cell Press. Molecular Therapy.
  6. Saade, D., Bhurucha-Goebel, D., Foley, A.R., Neuhaus, S.B., Soldatos, A., Hu, Y., Hewitt, M., Calcedo del Hoyo, R., Jacobson, S., and Liebovitch, E. (2018). Review of CSF and Peripheral Immune Responses Following Intrathecal Gene Transfer for Giant Axonal Neuropathy, Cell Press. Molecular Therapy.
  7. Bharucha-Goebel, D., Saade, D., Soldatos, A., Kang, E., Del Calcedo, R., Hu, Y., Liebovitch, E., Jacobson, S., Rybin, D., and Foley, A.R. (2019). Immune Analysis Following Intrathecal Gene Transfer: 3-Year Data from Clinical Intrathecal Gene Transfer Trial for Patients with Giant Axonal Neuropathy, Cell Press. Molecular Therapy.
  8. Kuntz, N., Shieh, P.B., Smith, B., Bonnemann, C.G., Dowling, J.J., Lawson, M.W., Muller-Felber, W., Noursalehi, M., Rico, S., and Servais, L. (2018). Aspiro Phase 1/2 Gene Therapy Trial in X-Linked Myotubular Myopathy (Xlmtm): Preliminary Safety and Efficacy Findings, Cell Press. Molecular Therapy.
  9. (2020, January 28). Pfizer Presents Initial Clinical Data on Phase 1B Gene Therapy Study for Duchenne Muscular Dystrophy (DMD). Available online: https://investors.pfizer.com/investor-news/press-release-details/2019/Pfizer-Presents-Initial-Clinical-Data-on-Phase-1b-Gene-Therapy-Study-for-Duchenne-Muscular-Dystrophy-DMD/default.aspx.

Cited by

See all 113

Metadata

Authors
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M.
Affiliations
  • University of Florida (US)
  • AavantiBio, Inc., Gainesville, FL 32601, USA
  • Harvard University (US)
Corresponding author
Corti, Manuela
Venue
Brain Sciences
Publisher
MDPI AG
Published
2020-02-22
Volume
10
Issue
2
Pages
119
ISSN
2076-3425 (ISSN-L)
OpenAlex
W3007981561
Cited by
112
References
92
Citations by year
2026: 10 · 2025: 14 · 2024: 17 · 2023: 14 · 2022: 29 · 2021: 21 · 2020: 7
FWCI
2.53
Type
journal article
Language
en
Open access
Locations
  • Brain Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (5T32DK074367-04)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
  • Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
Keywords
adeno-associated virus, AAV gene therapy, neuroinflammation, neurodegenerative diseases, spinal muscular atrophy, Canavan disease, Parkinson's disease, Friedreich's ataxia, immunosuppression, dorsal root ganglia, myelopathy, mononuclear cell infiltration, neuroinflammation biomarkers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. https://app.cochat.ai/papers/10.3390/brainsci10020119
The paper
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020). Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. Brain Sciences. https://doi.org/10.3390/brainsci10020119

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.